<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03672097</url>
  </required_header>
  <id_info>
    <org_study_id>CS747S-B-A4003</org_study_id>
    <nct_id>NCT03672097</nct_id>
  </id_info>
  <brief_title>Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)</brief_title>
  <official_title>Phase IV, Non-comparative, Open Label, Multicenter, 28-Week Switching Study of Prasugrel Maintenance Dose From Clopidogrel in Patients With Acute Coronary Syndrome (ACS) Who Underwent a Percutaneous Coronary Intervention (PCI) in Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase IV, multicenter trial is designed to assess the efficacy of prasugrel in
      preventing the formation of blood clots in Taiwanese patients with ACS who have been treated
      with PCI.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 16, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in P2Y12 Reaction Units (PRU) during Period 1</measure>
    <time_frame>Period 1: Baseline, Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Major Bleeding Events during Period 2</measure>
    <time_frame>Period 2: End of Week 4 through Week 28 (optionally up to a maximum 12 months of P2Y12 inhibitor treatment after ACS underwent PCI)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With High On-Treatment Platelet Reactivity (HTPR) during Period 1</measure>
    <time_frame>Baseline through Week 4</time_frame>
    <description>HTPR is defined as PRU &gt;235</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Platelet Inhibition during Period 1</measure>
    <time_frame>Baseline through Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events of Special Interest during Period 1</measure>
    <time_frame>Baseline through Week 4</time_frame>
    <description>Categories: minor bleeding events, clinically relevant bleeding events, major adverse cardiovascular events (MACE), all cause deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events of Special Interest during Period 2</measure>
    <time_frame>End of Week 4 through Week 28 (optionally up to a maximum 12 months of P2Y12 inhibitor treatment after ACS underwent PCI)</time_frame>
    <description>Categories: minor bleeding events, clinically relevant bleeding events, major adverse cardiovascular events (MACE), all cause deaths</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Coronary Syndrome (ACS)</condition>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with ACS who underwent PCI, and were previously taking clopidogrel, receive a maintenance dose (MD) of prasugrel for a total of 28 weeks (optionally up to a maximum 12 months of P2Y12 inhibitor treatment after ACS underwent PCI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Prasugrel, oral tablets, containing 3.75 mg per tablet</description>
    <arm_group_label>Prasugrel</arm_group_label>
    <other_name>Efient®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is within the age limits and has signed informed consent

          -  Weighs at least 50 kg

          -  Had a previous diagnosis of ACS (UA, STEMI, or NSTEMI), underwent PCI, and received
             one of the following treatments:

               -  Clopidogrel MD of 75 mg and aspirin 81-100 mg for 2-8 weeks following clopidogrel
                  loading dose (LD) of 300 mg or 600 mg at the time of PCI

               -  Ticagrelor MD of 90 mg twice daily (BID) and aspirin 81-100 mg for 1-4 weeks and
                  switching to clopidogrel MD of 75 mg and aspirin 81-100 mg for 2-4 weeks
                  following ticagrelor LD of 180 mg at the time of PCI

               -  Clopidogrel MD 75 mg and aspirin 81-100 mg for 2-8 weeks following ticagrelor LD
                  of 180 mg at the time of PCI

               -  Or based on investigator's judgment with at least 2 weeks continued use of
                  clopidogrel MD and aspirin 81-100 mg per day before switching to prasugrel and
                  maximum 8 weeks P2Y12 inhibitors MD treatment (prasugrel is not allowed)

          -  Is willing and able to abide by the rules of the research unit and study restrictions

          -  If a woman of child-bearing potential, has a negative serum pregnancy test at
             screening

          -  Agrees to use at least one method of contraception during the study

        Exclusion Criteria:

          -  Has active bleeding, significant risk of hemorrhage, or unusual susceptibility to
             bleed

          -  Had previous hemorrhagic stroke at any time, or transient ischemic attack (TIA) or
             ischemic stroke within 3 months before the informed consent date

          -  Has known allergies or hypersensitivity to prasugrel, aspirin, or any of their
             excipients

          -  Has significant hypertension at screening or baseline assessment

          -  Has hemoglobin levels &lt;10.5 g/dL or hematocrit levels &lt;30%

          -  Has severe left ventricular systolic dysfunction, ejection fraction &lt;30%

          -  Is currently undergoing hemodialysis

          -  Has evidence of severe hepatic disease or any of the following: serum alanine
             transaminase or aspartate transaminase ≥3 times the upper limit of normal (ULN); or
             bilirubin ≥2 times the ULN at screening

          -  Has any clinical laboratory result performed at screening that is determined to be
             detrimental to the patient or could compromise the study as determined the
             Investigator

          -  Has previously participated in this study or in another interventional trial that is
             not compatible with this study

          -  Has evidence of significant active neuropsychiatric disease, alcohol abuse or drug
             abuse as determined by the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheng Hsin General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Linkou</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 13, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Percutaneous Coronary Intervention (PCI)</keyword>
  <keyword>ST elevation myocardial infarction (STEMI)</keyword>
  <keyword>Non-ST elevation myocardial infarction [NSTEMI]</keyword>
  <keyword>Unstable angina (UA)</keyword>
  <keyword>Prasugrel</keyword>
  <keyword>ACS-PCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/daiichi-sankyo/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

